A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

The pharmaceutical company posted higher earnings and sales for the second quarter, and said longtime financial chief Harry ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.

Investing.com -- Novartis (SIX: NOVN) on Thursday posted a 24% rise in second-quarter net income to $4 billion, as sales of key therapies including Kisqali and Entresto drove performance in the U.S.

Novartis (SIX:NOVN) reported a 24% surge in Q2 net income to $4 billion, driven by robust demand for key therapies like Kisqali, Entresto, and Kesimpta. Earnings per share rose 29% to $2.07, supported ...

A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

The company's quarterly core operating profit--the company's preferred earnings metric, which strips out exceptional and other one-off items--is forecast at $5.75 billion, according to the same ...

Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with ...